Adjuvant whole-lung radiation with or without adriamycin treatment in osteogenic sarcoma.
Eighteen consecutive patients with osteogenic sarcoma were treated after initial surgery with 2000 rads of whole-lung radiation for 21--28 days. Eleven of these patients went on to receive adriamycin (20 mg/m2 X 3 days every 6 weeks). Three of seven evaluable patients are free of disease in the radiation group (median time to recurrence, 130 days) while six of ten evaluable patients are free of disease in the radiation + adriamycin group (median time to recurrence, 310+ days). These results are similar to published experience with whole-lung radiation and adriamycin alone.
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D002648:Child; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging*; D008175:Lung Neoplasms / Q000517:prevention & control*; D008297:Male; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D011859:Radiography; D013997:Time Factors
D004317:Doxorubicin